Work

Prognostic impact of early complete metabolic response on FDG-PET, in BRAF V600 mutant metastatic melanoma patients treated with combination vemurafenib & cobimetinib

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx377.012

Authors: W. Xu, J. Frederickson, J. Callahan, A. Ribas, R. Gonzalez, A.C. Pavlick, O. Hamid, T. Gajewski, I. Puzanov, A. Daud, D. Colburn, N. Choong, M. Wongchenko, R. Hicks, G.A. McArthur

Institutions: Peter MacCallum Cancer Centre, Genentech, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Colorado Cancer Center, New York University, Angeles Clinic and Research Institute, University of Chicago, Roswell Park Comprehensive Cancer Center, University of California, San Francisco

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Les Laboratories Pierre Fabre, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research, Incyte, National Institute for Health and Care Research, Eisai, Genentech

OpenAlex ID: W2762688207

FWCI:

Cites:

Cited by:

Related to: 10